Physicochemical Characterization of Iron Carbohydrate Colloid Drug Products

AAPS Journal

Volumn 19, Issue 5, 2017, Pages 1359-1376

  Zou, Peng ^a   Tyner, Katherine ^a   Raw, Andre ^a   Lee, Sau ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

ferumoxytol; iron colloid; iron dextran; iron sucrose; sodium ferric gluconate

Indexed keywords

BLEOMYCIN; CARBOHYDRATE; FERRIC CARBOXYMALTOSE; FERRIC GLUCONATE; FERRIC HYDROXIDE; FERROZINE; FERUMOXYTOL; IRON; IRON DEXTRAN; IRON ISOMALTOSIDE; IRON SACCHARATE; MONOFER; UNCLASSIFIED DRUG; FERRIC ION; SACCHARIC ACID;

ARTICLE; ATOMIC FORCE MICROSCOPY; CHEMICAL COMPOSITION; CHEMICAL INTERACTION; CRYSTAL STRUCTURE; DNA DAMAGE; ELECTRON DIFFRACTION; ELECTRON SPIN RESONANCE; ELEMENTAL ANALYSIS; INFRARED SPECTROSCOPY; IRON CHELATION; MAGNETISM; MOLECULAR WEIGHT; MOSSBAUER SPECTROSCOPY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; PHYSICAL CHEMISTRY; POLAROGRAPHY; RAMAN SPECTROMETRY; STOICHIOMETRY; SURFACE CHARGE; THERMAL ANALYSIS; TRANSMISSION ELECTRON MICROSCOPY; ULTRAVIOLET SPECTROSCOPY; VALIDATION PROCESS; X RAY ABSORPTION SPECTROSCOPY; X RAY DIFFRACTION; X RAY POWDER DIFFRACTION; CHEMISTRY; COLLOID; DRUG DEVELOPMENT;

COLLOIDS; DRUG DISCOVERY; FERRIC COMPOUNDS; GLUCARIC ACID; IRON-DEXTRAN COMPLEX; MOLECULAR WEIGHT; PARTICLE SIZE;

EID: 85026498488     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-017-0126-0     Document Type: Article

References (83)

1. Danielson BG. Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol: JASN. 2004;15(Suppl 2):S93–8.
2. Silverstein SB, Rodgers GM. Parenteral iron therapy options. Am J Hematol. 2004;76(1):74–8.
3. Toblli JE, Cao G, Oliveri L, Angerosa M. Differences between original intravenous iron sucrose and iron sucrose similar preparations. Arzneimittelforschung. 2009;59(4):176–90.
4. Jahn MR, Andreasen HB, Futterer S, Nawroth T, Schunemann V, Kolb U, et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm: Off J Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV. 2011;78(3):480–91.
5. FDA. Draft guidance on iron sucrose. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM297630.pdf2012.
6. FDA. Draft guidance on ferumoxytol http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM333051.pdf2012.
7. FDA. Draft guidance on sodium ferric gluconate complex. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM358142.pdf2013.
8. FDA. Draft guidance on ferric carboxymaltose. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM495022.pdf2016.
9. FDA. Draft guidance on iron dextran https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM520240.pdf2016. Available from: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM520240.pdf.
10. EMA. Reflection paper on the data requirements for intravenous iron-based nano-colloidal products developed with reference to an innovator medicinal product. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/03/WC500184922.pdf2015.
11. Kudasheva DS, Lai J, Ulman A, Cowman MK. Structure of carbohydrate-bound polynuclear iron oxyhydroxide nanoparticles in parenteral formulations. J Inorg Biochem. 2004;98(11):1757–69.
12. Bhavesh S, Barot PBP, Shelat PK, Shah GB, Mehta DM, Pathak TV. Physicochemical and toxicological characterization of sucrose bound polynuclear iron oxyhydroxide formulations. J Pharm Investig. 2015;45:35–49.
13. Balakrishnan VS, Rao M, Kausz AT, Brenner L, Pereira BJ, Frigo TB, et al. Physicochemical properties of ferumoxytol, a new intravenous iron preparation. Eur J Clin Investig. 2009;39(6):489–96.
14. Yang YS, Shah RB, Faustino PJ, Raw A, Yu LX, Khan MA. Thermodynamic stability assessment of a colloidal iron drug product: sodium ferric gluconate. J Pharm Sci. 2010;99(1):142–53.
15. Neiser S, Rentsch D, Dippon U, Kappler A, Weidler PG, Gottlicher J, et al. Physico-chemical properties of the new generation IV iron preparations ferumoxytol, iron isomaltoside 1000 and ferric carboxymaltose. Biometals: Int J Role Metal Ions Biol Biochem Med. 2015;28(4):615–35.
16. Funk F, Long GJ, Hautot D, Buchi R, Christl I, Weidler PG. Physical and chemical characterization of therapeutic iron containing materials: a study of several superparamagnetic drug formulations with the beta-FeOOH or ferrihydrite structure. Hyperfine Interact. 2001;136(1–2):73–95.
17. Meier T, Schropp P, Pater C, Leoni AL, Van VKT, Elford P. Physicochemical and toxicological characterization of a new generic iron sucrose preparation. Arzneimittel-Forsch. 2011;61(2):112–9.
18. Shah RB, Yang YS, Khan MA, Raw A, Yu LX, Faustino PJ. Pharmaceutical characterization and thermodynamic stability assessment of a colloidal iron drug product: iron sucrose. Int J Pharm. 2014;464(1–2):46–52.
19. Van Wyck D, Anderson J, Johnson K. Labile iron in parenteral iron formulations: a quantitative and comparative study. Nephrol Dial Transplant: Off Publ Eur Dial Transplant Assoc – Eur Renal Assoc. 2004;19(3):561–5.
20. Kohgo Y, Ikuta K, Ohtake T, Torimoto Y, Kato J. Body iron metabolism and pathophysiology of iron overload. Int J Hematol. 2008;88(1):7–15.
21. USP. USP monographs: iron sucrose injection. 2016.
22. Merli D, Profumo A, Dossi C. An analytical method for Fe(II) and Fe(III) determination in pharmaceutical grade iron sucrose complex and sodiumferric gluconate complex. J Pharm Anal. 2012;2(6):450–3.
23. Jahn MR, Mrestani Y, Langguth P, Neubert RHH. CE characterization of potential toxic labile iron in colloidal parenteral iron formulations using off-capillary and on-capillary complexation with EDTA. Electrophoresis. 2007;28(14):2424–9.
24. Futterer S, Andrusenko I, Kolb U, Hofmeister W, Langguth P. Structural characterization of iron oxide/hydroxide nanoparticles in nine different parenteral drugs for the treatment of iron deficiency anaemia by electron diffraction (ED) and X-ray powder diffraction (XRPD). J Pharm Biomed. 2013;86:151–60.
25. von Bonsdorff L, Lindeberg E, Sahlstedt L, Lehto J, Parkkinen J. Bleomycin-detectable iron assay for non-transferrin-bound iron in hematologic malignancies. Clin Chem. 2002;48(2):307–14.
26. Gutteridge JMC, Rowley DA, Halliwell B. Superoxide-dependent formation of hydroxyl radicals in the presence of iron salts—detection of free iron in biological-systems by using bleomycin-dependent degradation of DNA. Biochem J. 1981;199(1):263–5.
27. Burkitt MJ, Milne L, Raafat A. A simple, highly sensitive and improved method for the measurement of bleomycin-detectable iron: the ‘catalytic iron index’ and its value in the assessment of iron status in haemochromatosis. Clin Sci. 2001;100(3):239–47.
28. Breuer W, Ronson A, Slotki IN, Abramov A, Hershko C, Cabantchik ZI. The assessment of serum nontransferrin-bound iron in chelation therapy and iron supplementation. Blood. 2000;95(9):2975–82.
29. Garcic A. Highly sensitive, simple determination of serum iron using chromazurol-B. Clin Chim Acta. 1979;94(2):115–9.
30. Perry RD, Sanclemente CL. Determination of iron with bathophenanthroline following an improved procedure for reduction of iron(III) ions. Analyst. 1977;102(1211):114–9.
31. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33(9):941–51.
32. Gutierrez L, Morales MD, Lazaro FJ. Magnetostructural study of iron sucrose. J Magn Magn Mater. 2005;293(1):69–74.
33. Bullivant JP, Zhao S, Willenberg BJ, Kozissnik B, Batich CD, Dobson J. Materials characterization of feraheme/ferumoxytol and preliminary evaluation of its potential for magnetic fluid hyperthermia. Int J Mol Sci. 2013;14(9):17501–10.
34. Wu Y, Petrochenko P, Chen L, Wong SY, Absar M, Choi S, et al. Core size determination and structural characterization of intravenous iron complexes by cryogenic transmission electron microscopy. Int J Pharm. 2016;505(1–2):167–74.
35. Andersen HL, Christensen M. In situ powder X-ray diffraction study of magnetic CoFe2O4 nanocrystallite synthesis. Nano. 2015;7(8):3481–90.
36. Iman M, Huang Z, Szoka FC Jr, Jaafari MR. Characterization of the colloidal properties, in vitro antifungal activity, antileishmanial activity and toxicity in mice of a di-stigma-steryl-hemi-succinoyl-glycero-phosphocholine liposome-intercalated amphotericin B. Int J Pharm. 2011;408(1–2):163–72.
37. Barot BS, Parejiya PB, Mehta DM, Shelat PK, Shah GB. Physicochemical and structural characterization of iron-sucrose formulations: a comparative study. Pharm Dev Technol. 2014;19(5):513–20.
38. Koralewski M, Pochylski M, Gierszewski J. Magnetic properties of ferritin and akaganeite nanoparticles in aqueous suspension. J Nanopart Res. 2013;15(9):1902.
39. Frankel RB, Papaefthymiou GC, Watt GD. Variation of superparamagnetic properties with iron loading in mammalian ferritin. Hyperfine Interact. 1991;66(1–4):71–82.
40. Prester M, Drobac D, Marohnic Z. Magnetic dynamics studies of the newest-generation iron deficiency drugs based on ferumoxytol and iron isomaltoside 1000. J Appl Phys. 2014;116(4).
41. EMA, CHMP assessment report Rienso; common name: ferumoxytol; procedure no.: EMEA/H/C/002215. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002215/WC500129751.pdf2012.
42. Wang XM, Zhu MQ, Koopal LK, Li W, Xu WQ, Liu F, et al. Effects of crystallite size on the structure and magnetism of ferrihydrite. Environ Sci-Nano. 2016;3(1):190–202.
43. Guyodo YBP, Till JL, Ona-Nguema G, Lagroix F and Menguy N. Constraining the origins of the magnetism of lepidocrocite (γ-FeOOH): a Mössbauer and magnetization study. Front Earth Sci. 2016;4(28).
44. Bendersky LA, Gayle FW. Electron diffraction using transmission electron microscopy. J Res Natl Inst Stan. 2001;106(6):997–1012.
45. Schamp CT, Jesser WA. On the measurement of lattice parameters in a collection of nanoparticles by transmission electron diffraction. Ultramicroscopy. 2005;103(2):165–72.
46. Mugnaioli E, Capitani G, Nieto F, Mellini M. Accurate and precise lattice parameters by selected-area electron diffraction in the transmission electron microscope. Am Mineral. 2009;94(5–6):793–800.
47. Gupta A, Pratt RD, Crumbliss AL. Ferrous iron content of intravenous iron formulations. Biometals: Int J Role Metal Ions Biol Biochem Med. 2016;29(3):411–5.
48. Murad E. Magnetic properties of microcrystalline iron(III) oxides and related materials as reflected in their Mossbauer spectra. Phys Chem Miner. 1996;23(4–5):248–62.
49. Fultz B. Mössbauer spectrometry. In: Kaufmann E, editor. Characterization of materials. New York: Wiley; 2011.
50. Oshtrakh MI, Semionkin VA, Prokopenko PG, Milder OB, Livshits AB, Kozlov AA. Hyperfine interactions in the iron cores from various pharmaceutically important iron-dextran complexes and human ferritin: a comparative study by Mossbauer spectroscopy. Int J Biol Macromol. 2001;29(4–5):303–14.
51. Coe EM, Bowen LH, Bereman RD, Speer JA, Monte WT, Scaggs L. A study of an iron dextran complex by Mossbauer-spectroscopy and X-ray-diffraction. J Inorg Biochem. 1995;57(1):63–71.
52. Sartoratto PPC, Caiado KL, Pedroza RC, da Silva SW, Morais PC. The thermal stability of maghemite-silica nanocomposites: an investigation using X-ray diffraction and Raman spectroscopy. J Alloy Compd. 2007;434:650–4.
53. da Silva SW, Pedroza RC, Sartoratto PPC, Rezende DR, Neto AVD, Soler MAG, et al. Raman spectroscopy of cobalt ferrite nanocomposite in silica matrix prepared by sol-gel method. J Non-Cryst Solids. 2006;352(9–20):1602–6.
54. Szybowicz M, Koralewski M, Karon J, Melnikova L. Micro-Raman spectroscopy of natural and synthetic ferritins and their mimetics. Acta Phys Pol A. 2015;127(2):534–6.
55. Ascone I. X-ray absorption spectroscopy for beginners http://www.iucr.org/__data/assets/pdf_file/0004/60637/IUCr2011-XAFS-Tutorial_-Ascone.pdf2011 [Nov 3, 2015].
56. Theil EC, Sayers DE, Brown MA. Similarity of the structure of ferritin and iron-dextran (Imferon) determined by extended X-ray absorption fine-structure analysis. J Biol Chem. 1979;254(17):8132–4.
57. Coe EM, Bowen LH, Speer JA, Wang ZH, Sayers DE, Bereman RD. The recharacterization of a polysaccharide iron complex (Niferex). J Inorg Biochem. 1995;58(4):269–78.
58. Slavov L, Abrashev MV, Merodiiska T, Gelev C, Vandenberghe RE, Markova-Deneva I, et al. Raman spectroscopy investigation of magnetite nanoparticles in ferrofluids. J Magn Magn Mater. 2010;322(14):1904–11.
59. Oshtrakh MI, Milder OB, Semionkin VA. Determination of the iron state in ferrous iron containing vitamins and dietary supplements: application of Mossbauer spectroscopy. J Pharm Biomed Anal. 2006;40(5):1281–7.
60. Dobosz B, Krzyminiewski R, Schroeder G, Kurczewska J. Electron paramagnetic resonance as an effective method for a characterization of functionalized iron oxide. J Phys Chem Solids. 2014;75(5):594–8.
61. Sur SK, Cooney TF. Electron-paramagnetic resonance study of iron(III) and manganese(II) in the glassy and crystalline environments of synthetic fayalite and tephroite. Phys Chem Miner. 1989;16(7):693–6.
62. Somsook E, Hinsin D, Buakhrong P, Teanchai R, Mophan N, Pohmakotr M, et al. Interactions between iron(III) and sucrose, dextran, or starch in complexes. Carbohyd Polym. 2005;61(3):281–7.
63. Ohnishi T, Asakura T, Yonetani T, Chance B. Electron paramagnetic resonance studies at temperatures below 77 degrees K on iron-sulfur proteins of yeast and bovine heart submitochondrial particles. J Biol Chem. 1971;246(19):5960–4.
64. Wardzynski W, Baran M, Szymczak H. Electron-paramagnetic resonance of Fe-3+ in bismuth germanium oxide single-crystals. Physica B & C. 1981;111(1):47–50.
65. Beardwood P, Gibson JF, Bertrand P, Gayda JP. Temperature-dependence of the electronic spin-lattice relaxation-time in a 2-iron-2-sulfur model complex. Biochim Biophys Acta. 1983;742(2):426–33.
66. GarciaArmada P, Losada J, de VicentePerez S. Cation analysis scheme by differential pulse polarography. J Chem Educ. 1996;73(6):544–7.
67. Arcon I, Kolar J, Kodre A, Hanzel D, Strlic M. XANES analysis of Fe valence in iron gall inks. X-Ray Spectrom. 2007;36(3):199–205.
68. Kastele X, Sturm C, Klufers P. C-13 NMR spectroscopy as a tool for the in situ characterisation of iron-supplementing preparations. Eur J Pharm Biopharm. 2014;86(3):469–77.
69. Usselman RJ, Russek SE, Klem MT, Allen MA, Douglas T, Young M, et al. Temperature dependence of electron magnetic resonance spectra of iron oxide nanoparticles mineralized in Listeria innocua protein cages. J Appl Phys. 2012;112(8):4701–6.
70. Evans DF. The determination of the paramagnetic susceptibility of substances in solution by nuclear magnetic resonance. J Chem Soc. 1959:2003–5.
71. Braun A, Couteau O, Franks K, Kestens V, Roebben G, Lamberty A, et al. Validation of dynamic light scattering and centrifugal liquid sedimentation methods for nanoparticle characterisation. Adv Powder Technol. 2011;22(6):766–70.
72. NIST-NCL. NIST - NCL joint assay protocol: measuring the size of nanoparticles in aqueous media using batch-mode dynamic light scattering 2010.
73. Holloway C, Mueller-Berghaus J, Lima BS, Lee S, Wyatt JS, Nicholas JM, et al. Scientific considerations for complex drugs in light of established and emerging regulatory guidance. Ann N Y Acad Sci. 2012;1276:26–36.
74. Borchard G, Fluhmann B, Muhlebach S. Nanoparticle iron medicinal products—requirements for approval of intended copies of non-biological complex drugs (NBCD) and the importance of clinical comparative studies. Regul Toxicol Pharmacol. 2012;64(2):324–8.
75. Schellekens H, Klinger E, Muhlebach S, Brin JF, Storm G, Crommelin DJ. The therapeutic equivalence of complex drugs. Regul Toxicol Pharmacol: RTP. 2011;59(1):176–83.
76. Luitpold Pharmaceuticals Inc., 2005 Citizen petition: generic equivalents and pharmaceutical alternatives of iron sucrose injection, USP (Docket No. FDA-2005-P-0319). https://www.regulations.gov/document?D=FDA-2005-P-0319-0019
77. Watson Pharma Inc., 2004 Citizen petition on ferrlecit (Docket No. FDA-2004-P-0070). https://www.fda.gov/ohrms/dockets/dailys/04/feb04/021304/04p-0070-cp00001-01-vol1.pdf.
78. Rottembourg J, Kadri A, Leonard E, Dansaert A, Lafuma A. Do two intravenous iron sucrose preparations have the same efficacy? Nephrol Dial Transplant: Off Publ Eur Dial Transplant Assoc - Eur Renal Assoc. 2011;26(10):3262–7.
79. Rottembourg JGA, Diaconita M, Kadri A. The complete study of the switch from iron-sucrose originator to iron-sucrose similar and vice versa in hemodialysis patients. J Kidney. 2016;2(1):110.
80. Stein J, Dignass A, Chow KU. Clinical case reports raise doubts about the therapeutic equivalence of an iron sucrose similar preparation compared with iron sucrose originator. Curr Med Res Opin. 2012;28(2):241–3.
81. Lee ES, Park BR, Kim JS, Choi GY, Lee JJ, Lee IS. Comparison of adverse event profile of intravenous iron sucrose and iron sucrose similar in postpartum and gynecologic operative patients. Curr Med Res Opin. 2013;29(2):141–7.
82. Toblli JE, Cao G, Oliveri L, Angerosa M. Comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat model. Inflamm Allergy Drug Targets. 2012;11(1):66–78.
83. Toblli JCG, Oliveri L, Angerosa M. Differences between the original iron sucrose complex iron sucrose complex Venofer® and the iron sucrose similar Generis®, and potential implications. Port J Nephrol Hypertension. 2009;23(1):53–63.